Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T
cells to engage and eliminate malignant B cells and is being developed for relapsed or …

Background Patients with relapsed or refractory large B-cell lymphoma after first-line
treatment who are not intended for haematopoietic stem-cell transplantation (HSCT) have …

As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large …

PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at
diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell …

Epigenetic alterations play an important role in tumor progression of diffuse large B-cell
lymphoma (DLBCL). However, the biological relevance of epigenetic gene mutations on …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …